NASDAQ · ARQT
Arcutis Biotherapeutics, Inc.
Smart money pulse
What insiders and funds are doing
- account_balance131 funds bought, 135 sold in the quarter ended Jun 30, 2026. 45 were new holders.
- info2 real insider sales in 12 months. $170K in total, not counting planned sales.
Pulse runs from −100 (everyone selling) to +100 (everyone buying). Half comes from insiders: real buyers vs. real sellers in the last 90 days (Form 4). Half comes from funds: funds that bought vs. funds that sold last quarter (13F). 13F is a snapshot of long positions on the last day of the quarter, filed up to 45 days later. It does not show short positions or trades since then. This is data, not advice.
Who owns it
275 funds report owning ARQT , up from 271
Last quarter
Who bought and who sold
Change in shares held, biggest funds first. Bars stop at ±100%.
Insider trades · last 12 months
Real buys and sales
Showing 1 real trades. Hidden: 1 stock grants, 1 option exercises, 2 planned 10b5-1 sales. Those happen on a schedule and say little about what an insider thinks. Bigger dot means a bigger trade.
Showing every filing. Dashed circles are routine: grants, tax withholding, option exercises and planned sales.
Top holders
Biggest funds in ARQT
| Fund | Owns | Value | Change |
|---|---|---|---|
| Montanova Capital, LLC | — | $326M | +1% |
| BlackRock, Inc. | — | $277M | +15% |
| Frazier Life Sciences Management, L.P. | — | $259M | +0% |
| Rubric Capital Management LP | — | $217M | +0% |
| Polar Capital Holdings Plc | — | $173M | +17% |
"Owns" is shares reported divided by shares outstanding.